Seven nalidixic acid-resistant clinical isolates of Escherichia coli were shown to carry resistance mutations in their gyrase A proteins. Six had serine-83 to leucine or tryptophan changes; the seventh had an aspartate-87 to valine substitution. The frequent occurrence of a mutation at serine-83 implies a key role for this residue in quinolone action.
Seven nalidixic acid-resistant clinical isolates of Escherichia coli were shown to carry resistance mutations in their gyrase A proteins. Six had serine-83 to leucine or tryptophan changes; the seventh had an aspartate-87 to valine substitution. The frequent occurrence of a mutation at serine-83 implies a key role for this residue in quinolone action.
Antimicrobial 4-quinolones exert their potent antagonistic effects on bacterial DNA replication by inhibiting DNA gyrase, an A2B2 tetrameric enzyme that catalyzes ATPdependent DNA supercoiling (4, 6-8, 10, 13, 23) . Gyrase promotes the negative supercoiling of DNA and the formation and resolution of interlocked DNA circles and knotted DNA by passing a DNA duplex through a transient enzymebridged double-strand break in DNA (22) . Studies with purified Escherichia coli DNA gyrase have shown that quinolones interfere with DNA breakage and reunion mediated by Tyr-122 of the 875-residue gyrase A subunits (6, 12) .
Genetic studies of 4-quinolone resistance in laboratory strains of E. coli K-12 have implicated a number of chromosomal loci in low-level resistance, whereas high-level resistance invariably maps at gyrA, which encodes the gyrase A protein (1, 6, 9, 15, (24) (25) (26) . The following quinolone resistance mutations in the gyrase A protein have been identified from sequence analysis of quinolone-resistant gyrA genes in E. coli KL16: Ser-83--Leu, Ser-83--*Trp, Asp-87--Asn, Gly-81--Cys, Ala-84--*Pro, Ala-67-*Ser, and Gln-106-->His (25) . In the only molecular study thus far of a resistant clinical isolate, we showed that mutation of Ser-83 to Trp in the gyrase A protein was responsible for quinolone resistance in a uropathogenic E. coli strain, 227, which was obtained from a patient treated with enoxacin (1). To provide much needed information on the molecular basis of resistance in clinical isolates, we describe here the analysis of an additional seven E. coli strains.
Uropathogenic clinical isolates of E. coli resistant to quinolones were obtained by Laura Piddock from several independent sources in Birmingham, England, between June 1984 and April 1985. Strains 58, 158, 202, 218, 227, 231, 233, and 235 were selected for study on the basis of their highlevel resistance to nalidixic acid (MICs, 31 to >1,000 ,g/ml) (2) (see Fig. 3 ). Several of the strains, 58, 202, and 227, were shown to contain a DNA gyrase A subunit that reconstituted a quinolone-resistant gyrase activity (2) . Using a restriction fragment length polymorphism analysis, we showed that all strains except strain 202 carried an amino acid substitution of unknown identity at Asp-82 or Ser-83 of the gyrase A protein (5) . We applied the polymerase chain reaction (PCR) in concert with rapid cloning-DNA sequence analysis to identify these gyrA mutations at the nucleotide level.
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High-molecular-weight chromosomal DNA was prepared from each strain (17) and subjected to PCR by using two 20-mer oligonucleotide primers, 5'-TACACCGGTCAACAT TGAGG and 5'-TTAATGATTGCCGCCGTCGG, which were identical in sequence to nucleotide positions 24 to 43 or complementary in sequence to positions 652 to 671 of the E. coli K-12 gyrA gene, respectively (21) (Fig. 2) . Although DNA sequences of cloned 582-bp gyrA fragments exhibited several nucleotide differences compared with that of the quinolone-susceptible E. coli K-12 gyrA gene, only a single coding change was present in each case (Fig. 3) Fig. 2 and 3) . The nature of these DNA sequence changes is consistent with our previous restriction fragment length polymorphism results ( Fig. 3) (5) . Mutation of Ser-83 to either Leu or Trp has been shown to confer quinolone resistance in nonclinical isolates of E. coli (25, 26) , e.g., N-51 and P-18 (Fig. 3) . We found the same mutations in seven nalidixic acid-resistant clinical isolates (MICs, 125 to >1,000 ,ug/ml), including the previously described strain 227 (1). We cannot exclude the possibility that other mutations contribute to resistance in these clinical isolates. Indeed, among the Ser-83--Leu gyrA mutants, strain 218 exhibited higher resistance to nalidixic acid and other quinolones, including ciprofloxacin, (Fig. 3) and grew less well than the other strains did, suggesting the presence of additional mutations. However, we note that E. coli KL16 strains N-51 and P-18 had levels of quinolone resistance broadly similar to those of our clinical isolates (Fig. 3) (1, 25, 26) . Thus, the Ser-83 to Leu or Trp gyrase A mutations that we have identified may, in large part, be responsible for the resistance of the clinical strains.
Strain 202 carried an Asp-87--+Val substitution in its gyrase A protein which maps in the same region of the polypeptide chain as the other known resistance mutations, i.e., adjacent to catalytic Tyr-122. For this strain the quinolone MICs were the lowest of those for the clinical isolates examined here (Fig. 3) , and the gyrase A protein partially purified from the strain was less resistant to quinolone inhibition than was the Ser-83--Trp protein (2) . It is significant that mutation of Asp-87 to Asn in the gyrase A protein Asterisks indicate nucleotide differences with the E. coli KL16 gyrA sequence (top) (26) that result in amino acid changes (parentheses). Silent base changes are also indicated (the KL16 gyrA sequence [26] itself exhibits a silent change at nucleotide position 267 compared with that of another K-12 strain [21] ). Underlining denotes a Hinfl site, and numbers identify the positions of the deduced amino acid residues. The mutation in strain 227 conferring quinolone resistance has been determined previously (1) . Strains N-51, N-113, and P-18 are nalidixic acidand pipemidic acid-resistant KL16 strains whose quinolone resistance mutation has been mapped as shown previously (25) . The MICs of nalidixic acid (NAL) and ciprofloxacin (CIP) have been described previously for clinical isolates (2) and KL16 strains (26) . The MICs of nalidixic acid determined here (12a) confirmed the results of previous work (2), except for the somewhat higher values for strains 58, 231, and 233. Both nalidixic acid and ciprofloxacin MICs are in broad agreement with those determined independently by L. Piddock (16) . is responsible for quinolone resistance in KL16 strain N-113 (Fig. 3) (25) . Although genetic proof is awaited, these considerations identify the Asp-87-Val substitution as a strong candidate as a resistance mutation.
Interestingly, examination of silent nucleotide changes in the gyrA genes revealed four different patterns of DNA polymorphism (Table 1) . Four strains bearing the gyrase A Ser-83-*Leu mutation shared the same polymorphisms. Those gyrA genes encoding the Ser-83--Trp mutation shared another pattern of changes. It is conceivable that the mutations to Leu and Trp codons arose in the gyrA genes of distinct precursor strains.
The main conclusion of this study is that mutation of Ser-83 in the gyrase A protein frequently confers clinical resistance to quinolones, suggesting that it has a key role in quinolone action. This residue and others involved in resistance are located in a compact domain of the gyrase A protein responsible for enzymatic DNA breakage and reunion ( Fig. 1) (18) . Serine-83 appears to fulfill an important function because it is conserved in the gyrase A proteins of E. coli, Bacillus subtilis, and Staphylococcus aureus, while the Klebsiella pneumoniae protein has an analogous threonine residue which, likewise, carries a small aliphatic side chain bearing a hydroxyl group (3, 11, 14, 21) . It is not clear how substitution with Leu or Trp relieves quinolone inhibition of the gyrase-DNA complex (20) . These changes introduce a bulkier hydrophobic side chain which could interfere with quinolone binding. Alternatively, the serine (threonine) OH group could participate in a key hydrogen-bonding or metal-liganding interaction essential for quinolone action. Resolution of these questions requires structural information on the gyrase complex and its mutants.
